Eggermont, A M M <br/><br/>
Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.  [electronic resource] 

 -  The Lancet. Oncology  Jun 2015 
 - e262 p.  digital 
<br/><br/> Publication Type: Published Erratum 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(15)70271-8  doi